Entrada Therapeutics scores $59 mln Series A
Boston-based Entrada Therapeutics, a biotechnology company, has raised $59 million in Series A financing. The lead investors were 5AM Ventures and MPM Capital. Other participants in the round were Roche Venture Fund, MRL Ventures Fund and Agent Capital.
18 December 2018•1 min read
